{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T18:21:04Z","timestamp":1766427664919},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tazarotene is internationally accepted common name for ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate. It is a synthetic retinoid used for the topical treatment of mild to moderate plaque psoriasis, acne vulgaris and photo aging. To ensure the quality of drug product and drug substance, a LC\u2013MS compatible UHPLC method was developed for quantification of drug and its related substances. Stationary phase with fused core particle technology is used for the separation of impurities. Limit of quantification and limit of detection of the method are 0.1 and 0.03%, respectively. Precision of the method for Tazarotene and all its related substances is less than 2.2% RSD. The correlation coefficient is &gt;0.999. Accuracy of method is ranged from 95.3% to 107.0%. Application of this method in stability analysis has been demonstrated by analyzing stressed samples. Experimental design is used for the verification of robustness of the method. To ensure the safety, an in silico toxicity of the drug and its related substances were determined using TOPKAT and DEREK toxicity predictions Both UHPLC and in silico methods were validated as per the ICH Q2 and ICH M7 guidelines, which will enable a rapid product development of Tazarotene topical formulations while ensuring the safety and quality of product.<\/jats:p>","DOI":"10.1093\/chromsci\/bmz037","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T19:13:57Z","timestamp":1554491637000},"page":"625-635","source":"Crossref","is-referenced-by-count":4,"title":["Quantification and In Silico Toxicity Assessment of Tazarotene and its Impurities for a Quality and Safe Drug Product Development"],"prefix":"10.1093","volume":"57","author":[{"given":"NVVSS Narayana Murty","family":"Nagulakonda","sequence":"first","affiliation":[{"name":"Department of Analytical chemistry, Dr. Reddy\u2019s Laboratories Ltd., Hyderabad, Telangana, India"},{"name":"Department of Inorganic & Analytical Chemistry, Andhra University, Visakhapatnam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi Shekar","family":"Ananthula","sequence":"additional","affiliation":[{"name":"Department of Analytical chemistry, Dr. Reddy\u2019s Laboratories Ltd., Hyderabad, Telangana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Department of Analytical chemistry, Dr. Reddy\u2019s Laboratories Ltd., Hyderabad, Telangana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muguda Ravi Prasada","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Analytical chemistry, Dr. Reddy\u2019s Laboratories Ltd., Hyderabad, Telangana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gollapalli Nageswara","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Inorganic & Analytical Chemistry, Andhra University, Visakhapatnam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"issue":"6","key":"2019072703201070800_bmz037C1","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jaad.2016.01.011","article-title":"Use of topical retinoids by dermatologists and non-dermatologists in the management of acne vulgaris","volume":"74","author":"Sandra","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl1","key":"2019072703201070800_bmz037C2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mjd.2003.618","article-title":"Management of acne: a report from a Global Alliance to Improve Outcomes in Acne","volume":"49","author":"Gollnick","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"2019072703201070800_bmz037C3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2009.01.019","article-title":"New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group","volume":"60","author":"Thiboutot","year":"2009","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"2019072703201070800_bmz037C4","first-page":"S163","article-title":"Evidence-based recommendations for the diagnosis and treatment of pediatric acne; American Acne and Rosacea","volume":"131","author":"Eichenfield","year":"2013","journal-title":"Society"},{"issue":"8","key":"2019072703201070800_bmz037C5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/jdv.13776","article-title":"European evidence-based (S3) guidelines for the treatment of acne","volume":"30","author":"Nast","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"5","key":"2019072703201070800_bmz037C6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"12","key":"2019072703201070800_bmz037C7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1610-0387.2008.06741.x","article-title":"Topical retinoids in acne-an evidence-based overview","volume":"6","author":"Thielitz","year":"2008","journal-title":"Journal der Deutschen Dermatologischen Gesellschaf"},{"issue":"1","key":"2019072703201070800_bmz037C8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2133.2001.04276.x","article-title":"Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents","volume":"145","author":"Thielitz","year":"2001","journal-title":"British Journal of Dermatolog"},{"issue":"3","key":"2019072703201070800_bmz037C9","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1067\/S0190-9622(03)01154-X","article-title":"A review of the use of combination therapies for the treatment of acne vulgaris","volume":"49","author":"Leyden","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1\u20132","key":"2019072703201070800_bmz037C10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/BF01964720","article-title":"The in vivo and in vitro anti-inflammatory activity of CD271: a new retinoid-like modulator of cell differentiation","volume":"29","author":"Hensby","year":"1990","journal-title":"Agents and Actions"},{"issue":"1","key":"2019072703201070800_bmz037C11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MOP.0b013e3283425457","article-title":"Changing the topography of acne with topical medications","volume":"23","author":"Imahiyerobo-Ip","year":"2011","journal-title":"Current Opinion in Pediatrics"},{"key":"2019072703201070800_bmz037C12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4103\/0378-6323.72443","article-title":"Psoriasis in India: prevalence and pattern","volume":"76","author":"Dogra","year":"2010","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"key":"2019072703201070800_bmz037C13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpba.2007.11.004","article-title":"Impurities of tazarotene: isolation and structural characterisation","volume":"46","author":"Elisabetta","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"3","key":"2019072703201070800_bmz037C14","first-page":"1","article-title":"Topical tazarotene therapy for psoriasis, acne vulgaris, and photo aging","volume":"7","author":"Guenther","year":"2002","journal-title":"Skin Therapy Letters"},{"key":"2019072703201070800_bmz037C15","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1067\/mjd.2000.108321","article-title":"Pharmacokinetics and safety of tazarotene","volume":"43","author":"Alan","year":"2000","journal-title":"Journal of the American Academy of Dermatology"},{"key":"2019072703201070800_bmz037C16","author":"Analytical Procedures","year":"2018"},{"issue":"3","key":"2019072703201070800_bmz037C17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1039\/b9ay00240e","article-title":"HPTLC method for estimation of tazarotene in topical gel formulations and in vitro study","volume":"2","author":"Mrunali","year":"2010","journal-title":"Analytical Methods"},{"key":"2019072703201070800_bmz037C18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/dta.109","article-title":"Stability-indicating spectrophotometric methods for determination of tazarotene in the presence of its alkaline degradation product by derivative spectrophotometric techniques","volume":"2","author":"Badawy","year":"2010","journal-title":"Drug Testing and Analysis"},{"key":"2019072703201070800_bmz037C19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/dta.138","article-title":"Stability-indicating chemometric methods for the determination of tazarotene","volume":"2","author":"Ahmed","year":"2010","journal-title":"Drug Testing and Analysis"},{"issue":"10","key":"2019072703201070800_bmz037C20","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/jps.20427","article-title":"Disposition and biotransformation of the acetylenic, retinoid tazarotene in humans","volume":"94","author":"Mayssa","year":"2005","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"2019072703201070800_bmz037C21","first-page":"173","article-title":"Simultaneous determination of tazarotene and its active metabolite tazarotenic acid in mini pig plasma by LC\u2013MS\/MS and its application in pharmacokinetic study after topical administration of tazarotene gel","volume":"978\u2013979","author":"Ying","year":"2015","journal-title":"Journal of Chromatography B"},{"key":"2019072703201070800_bmz037C22","first-page":"1400","article-title":"Stability indicating RP-HPLC method development and validation for determination of process related impurities and degradation products of Tazarotene in Tazarotene topical formulation","volume":"3","author":"Chinmoy","year":"2012","journal-title":"Indo American Journal of Pharmaceutical Research"},{"key":"2019072703201070800_bmz037C23","year":"2016"},{"key":"2019072703201070800_bmz037C24","year":"2018"},{"key":"2019072703201070800_bmz037C25","year":"2018"},{"issue":"1","key":"2019072703201070800_bmz037C26","first-page":"367","article-title":"Establishing best practise in the application of expert review of mutagenicity under ICH M7 Regulatory Toxicology","volume":"73","author":"Barber","year":"2015","journal-title":"Pharmacology"},{"key":"2019072703201070800_bmz037C27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yrtph.2016.02.004","article-title":"Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses","volume":"77","author":"Amberg","year":"2016","journal-title":"Regulatory Toxicology Pharmacology"},{"key":"2019072703201070800_bmz037C28","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1081\/JLC-200053046","article-title":"UPLC: an introduction and review","volume":"28","author":"Michael","year":"2005","journal-title":"Journal of Liquid Chromatography & Related Technologies"},{"issue":"5","key":"2019072703201070800_bmz037C29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jpha.2013.02.005","article-title":"Fused-core particle technology in high-performance liquid chromatography: an overview","volume":"3","author":"Joseph","year":"2013","journal-title":"Journal of Pharmaceutical Analysis"},{"key":"2019072703201070800_bmz037C30","year":"2019"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/chromsci\/advance-article-pdf\/doi\/10.1093\/chromsci\/bmz037\/28543705\/bmz037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/chromsci\/article-pdf\/57\/7\/625\/29008868\/bmz037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T17:27:58Z","timestamp":1721150878000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/57\/7\/625\/5481795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4,30]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmz037","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,4,30]]}}}